-
Enprofylline
- indication:Used in the management of symptoms of asthma. Also used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.
- pharmacologypharmacology:
- mechanism: Enprofylline inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, enprofylline also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity.
- toxicity:
- absorprion: Rapidly absorbed from the digestive tract
- halflife: 1.9 hours
- roouteelimination:
- volumedistribution:
- clearance: